StonvexLoading…
StonvexStonvexStonvexCore line items from DOCS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-03-31 | Annual 2024 2024-03-31 | Annual 2023 2023-03-31 | Annual 2022 2022-03-31 |
|---|---|---|---|---|
Revenue | $570.40M | $475.42M | $419.05M | $343.55M |
Operating Income | $227.80M | $163.88M | $125.11M | $113.54M |
Net Income | $223.19M | $147.58M | $112.82M | $154.78M |
EPS (Diluted) | $1.11 | $0.72 | $0.53 | $0.70 |
Total Assets | $1.26B | $1.08B | $1.14B | $991.36M |
Total Liabilities | $181.68M | $177.98M | $170.77M | $112.76M |
Cash & Equivalents | $209.61M | $96.78M | $158.03M | $112.81M |
Free Cash Flow OCF − CapEx | $273.26M | $183.95M | $177.90M | $124.66M |
Shares Outstanding | 188.88M | 186.56M | 193.94M | 192.40M |